Masimo

The Danaher acquisition of Masimo was officially finalized on June 10, 2026, marking a significant clinical advancement for global healthcare technology pipelines. Danaher Corporation (NYSE: DHR), a prominent global science and technology innovator headquartered in Washington, announced the successful completion of the transaction to acquire Masimo Corporation. This acquisition infuses Masimo’s specialized pulse oximetry systems and advanced patient monitoring solutions directly into Danaher's expanding medical infrastructure. Following the close of the transaction, Masimo operates as a wholly-owned subsidiary of Danaher, causing Masimo common stock to officially cease trading on the Nasdaq Stock Market. To preserve its deep clinical market presence, the acquired business will continue to navigate the medical industry under its traditional, trusted Masimo brand. Organizationally, it will be positioned as a stand-alone operating company within Danaher's Diagnostics segment, deploying its proprietary sensor technology alongside established laboratory brands. Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach. Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher Corporate Guidance and Financial Integration Plans After the Danaher Acquisition of Masimo Addressing the immediate financial trajectory, Danaher announced that there is no change to its previously communicated second-quarter and full-year 2026 guidance ranges, which currently exclude the financial contributions of the newly acquired company. Executive leadership does not project a material financial contribution from Masimo during the second quarter of 2026. However, Danaher intends to formally update its full-year 2026 guidance framework during its upcoming second-quarter earnings release to explicitly incorporate Masimo’s projected baseline contributions. The definitive transaction materials specifying terms and consideration payable to former stockholders have been filed with the U.S. Securities and Exchange Commission. Corporate documentation outlines several essential risk parameters that could influence the execution of the Danaher acquisition of Masimo, such as debt obligations incurred to finance the deal, international tariffs, and uncertainties regarding artificial intelligence deployment. Financial analysts who track diagnostic sector shifts can review our internal reporting on Danaher segment performance to evaluate how these variables fit into broader operational timelines. As a global life sciences innovator, Danaher anchors its operational expansion on approximately 60,000 associates worldwide who are committed to accelerating the power of science to improve human health. This massive footprint relies heavily on the foundational Danaher Business System (DBS), a set of core principles designed to drive continuous improvement, reduce clinical development risks, and accelerate diagnostic accuracy. Deployed strategically, this methodology will support the scaling of Masimo's AI-enabled non-invasive software tools to a much wider international hospital base. Transaction and Entity Profiles Metric ClassificationParameter DetailsSource Reference VerificationAcquiring Corporate EntityDanaher Corporation (NYSE: DHR)Official press release textAcquisition Target EntityMasimo Corporation (Ex-NASDAQ)Official press release textTransaction Closing DateJune 10, 2026Effective date of corporate actionPrimary Product CategoryPulse oximetry & patient monitoring solutionsTarget core business focusCore Operational EnvironmentsAcute care treatment settingsTargeted clinical workflowsPost-Acquisition StatusWholly-owned subsidiary of DanaherFinal operational relationshipStock Market ActionCeased trading on the Nasdaq Stock MarketSecurities delisting consequence Segment Placement and Governance Parameter CategoryIntegration StrategyStructural SpecificationParent Corporate SegmentDanaher Diagnostics SegmentOperational segment allocationSubsidiary Governance ModelStand-alone operating companyManagement autonomy frameworkBrand Management PolicyRetains the original Masimo brand nameMarket-facing identity retentionSegment Executive LeadershipJulie Sawyer MontgomeryExecutive Vice President of DiagnosticsParent Operational FrameworkDanaher Business System (DBS)Operational excellence engineGlobal Associate FootprintApproximately 60,000 associates worldwideParent company workforce capacity Financial Guidance and Risk Vector Mapping Guidance ParameterCurrent Fiscal StatusRisk Factor Matrix ComponentsQ2 2026 Corporate GuidanceUnchanged (Excludes Masimo numbers)No material contribution expected in Q2Full-Year 2026 Guidance UpdateScheduled for second-quarter earnings releaseDependent on integration and global economicsRegulatory Filing LocationU.S. Securities and Exchange CommissionDefinitive transaction materials repositoryTransaction Financing ImpactDebt obligations incurred for financingOperational liquidity considerationTechnological Risk VariableDeployment and use of artificial intelligenceSoftware innovation and compliance uncertaintyGlobal Operational Risk VectorsTariffs, trade policies, and geopolitical eventsIncludes specific global health or regional conflicts